Longer PSA Monitoring in Patients With Persistent PSA May Reduce Overtreatment
By Elana Gotkine HealthDay Reporter
THURSDAY, March 27, 2025 -- Assessment of prostate-specific antigen (PSA) level for three months after radical prostatectomy (RP) for prostate cancer may minimize overtreatment, according to a study published online March 13 in JAMA Oncology.
Derya Tilki, M.D., from University Hospital Hamburg Eppendorf in Germany, and colleagues examined the time necessary to accurately document a persistent PSA level after RP in a cohort study. The study included patients with T1N0M0 to T3N0M0 prostate cancer treated with RP between 1992 and 2020 at two academic centers. The discovery cohort included 30,461 patients, and the validation cohort included 12,837 patients.
The researchers found that for patients with persistent versus undetectable PSA, a pre-RP PSA level >20 ng/mL versus ≤20 ng/mL was significantly associated with reduced all-cause mortality (ACM) risk and prostate cancer-specific mortality (PCSM) risk (adjusted hazard ratios, 0.69 and 0.41, respectively). These findings persisted after adjustment for prostate volume and were confirmed in the validation cohort for PCSM risk. In patients with a pre-RP PSA >20 ng/mL versus ≤20 ng/mL, there was more frequent and a shorter median time to post-RP radiation therapy plus androgen deprivation therapy (ADT) or ADT use (54.7 percent at a median of 2.68 months versus 34.8 percent at a median of 3.30 months). These treatment times were shorter than those to an undetectable PSA in observed patients (median, 2.96 versus 3.37 months). There was an association seen for increasing persistent PSA level with increased ACM and PSCM risks (adjusted hazard ratios, 1.14 and 1.27, respectively).
"The clinical significance of these findings is that they highlight the need to monitor PSA after RP for longer than the commonly practiced 1.5-month to 2.0-month interval before concluding a persistent PSA exists and initiating post-RP therapy to minimize the risk of overtreatment," the authors write.
One author disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Parent-Reported Firearm Storage Poor Estimator of Teen Perceived Access
MONDAY, June 16, 2025 -- Parent-reported firearm storage seems to be a poor estimator of teen perceived firearm access, according to a study published online June 10 in JAMA...
CT Colonography Cost-Effective, Clinically Effective for CRC Screening
MONDAY, June 16, 2025 -- Computed tomography colonography (CTC) is cost-effective and clinically effective for colorectal cancer (CRC) screening, according to a study published...
Global Incidence Rate of Rheumatoid Arthritis Increased From 1990 to 2021
MONDAY, June 16, 2025 -- The incidence rate of rheumatoid arthritis (RA) increased globally from 1990 to 2021, with the heaviest burden born by regions with a high...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.